Nonimmunosuppressive chemotherapy: EM011-treated mice mount normal T-cell responses to an acute lymphocytic choriomeningitis virus infection

Molecular Cancer Therapeutics

Volumn 6, Issue 11, 2007, Pages 2891-2899

  Aneja, Ritu ^a   Kalia, Vandana ^a   Ahmed, Rafi ^a   Joshi, Harish C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; EM 011; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC CHORIOMENINGITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOTHERAPY; CONTROLLED STUDY; EFFECTOR CELL; EXPERIMENTAL INFECTION; EXPERIMENTAL MOUSE; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS MENINGITIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; DIOXOLES; FEMALE; GRANZYMES; IMMUNE TOLERANCE; ISOQUINOLINES; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID TISSUE; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES;

EID: 36749086504     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0359     Document Type: Article

References (41)

1. Gallagher J. Supportive care for viral infections in cancer patients. Curr Opin Oncol 1991;3:643-7.
2. Devine SM, Wingard JR. Viral infections in severely immunocompromised cancer patients. Support Care Cancer 1994;2:355-68.
3. Joo HG. Altered maturation of dendritic cells by Taxol, an anticancer drug. J Vet Sci 2003;4:229-34.
4. Lee M, Yea SS, Jeon YJ. Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int J Immunopharmacol 2000;22:615-21.
5. Horwitz S, Cohen BD, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61.
6. Chabner BA, Horwitz SB, Clendennin NJ, Purvis JD. Vinca alkaloids. Cancer Chemother Biol Response Modif 1991;12:67-73.
7. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
8. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
9. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;8:353-74.
10. Pace A, Bove L, Nistico C, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996;61:409-11.
11. Theiss C, Meller M. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res 2000;299:213-24.
12. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000;424:563-76.
13. Zhou J, Gupta K, Aggarwal S, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003;63:799-807.
14. Aneja R, Vangapandu SN, Lopus M, et al. Synthesis of microtubule- interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol 2003;72:415-26.
15. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 2003;107:2486-92.
16. Landen JW, Lang R, McMahon SJ, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2003;62:4109-14.
17. Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC. Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther 2006;5:2366-77.
18. Oldstone MB, Blount P, Southern PJ, Lampert PW. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature 1986;321:239-43.
19. Ahmed R, Salmi A, Butler LD, Chiller JM, Oldstone MBA. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med 1984;160:521-40.
20. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-87.
21. + T cells. J Immunol 2000;164:3950.
22. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363.
23. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002;2:251-62.
24. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-45.
25. Matloubian M, Kolhekar SR, Somasundaram T, Ahmed R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J Virol 1993;67:7340-9.
26. + cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-63.
27. Blattman JN, Antia R, Soudive DJD, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002;195:657-64.
28. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human ah T cell receptor diversity. Science 1999;286:958-61.
29. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-402.
30. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
31. Bachmann MF, Barner M, Viola A, Kopf M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol 1999;29:291-9.
32. Cerwenka A, Morgan TM, Dutton RW. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol 1999;163:5535-43.
33. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111:837-51.
34. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
35. + T-cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2:415-22.
36. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001;2:423-9.
37. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG. Early programming of T-cell populations responding to bacterial infection. J Immunol 2000;165:6833-9.
38. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998;8:89-95.
39. Jelley-Gibbs DM, Lepak NM, Yen M, Swain SL. Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation. J Immunol 2000;165:5017-26.
40. Iezzi G, Scotet E, Scheidegger D, Lanzavecchia A. The interplay between the duration of TCR and cytokine signaling determines T-cell polarization. Eur J Immunol 1999;29:4092-101.
41. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322.